Connect with us

Technology

POMDOCTOR LIMITED Advances Strategic Evolution from Traffic Monetization to Value-Based Healthcare Payment

Published

2 days ago

on

Building a Four-Tier Revenue Structure Across B2C Services, AI-Enabled Chronic Disease Management, B2B Healthcare Services, and Pharmaceutical RWS/RWD

GUANGZHOU, China, Nov. 4, 2026 /PRNewswire/ — POMDOCTOR LIMITED (“Pomdoctor” or the “Company”) (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions, today provided an overview of its strategic evolution and business model transformation amid the rapid development of China’s digital healthcare industry. Since its establishment in 2010, Pomdoctor has progressively evolved from the industry’s early “traffic monetization” model toward a more diversified and value-oriented healthcare ecosystem, culminating in its current four-tier revenue structure spanning B2C healthcare services, AI-enabled chronic disease management, B2B enterprise and hospital services, and pharmaceutical real-world study (“RWS”) and real-world data (“RWD”) services.

From Traffic Monetization to Diversified Healthcare Services

Pomdoctor was established in 2010, when China’s digital healthcare industry was entering an early stage of transformation. At the time, the prevailing business model centered on “traffic monetization,” with online consultations and pharmaceutical e-commerce generating revenue primarily through user acquisition, engagement, and pharmaceutical sales. As major participants from the e-commerce and pharmaceutical sectors entered the market, competition intensified, placing increasing pressure on the sustainability and differentiation of this model.

Recognizing the structural limitations of relying primarily on user traffic and pharmaceutical transactions, including patients’ limited willingness to pay directly for healthcare services, constrained health insurance coverage, and limitations in advertising-based monetization, Pomdoctor began developing a more diversified business model. The Company expanded beyond a purely service-oriented model and introduced subscription-based offerings supported by more refined operations and specialized healthcare services, establishing an early foundation for recurring and diversified revenue generation.

Expansion into B2B and Hospital Services

As the digital healthcare industry continued to evolve, Pomdoctor further expanded into B2B services, leveraging its healthcare expertise and digital capabilities to provide digital marketing solutions for pharmaceutical companies. Over time, this business evolved from pharmaceutical-focused digital services toward deeper engagement with healthcare institutions, including public hospitals.

This transition enabled Pomdoctor to broaden its role within the healthcare ecosystem, from serving individual users to connecting patients, healthcare providers, pharmaceutical companies, and other enterprise stakeholders. The Company believes this accumulated experience and institutional connectivity have provided an important foundation for its subsequent expansion into higher-value healthcare services.

Leveraging AI and Data to Unlock New Value

With the emergence of artificial intelligence (“AI”) as a transformative force across the healthcare industry, Pomdoctor has continued to build on its existing capabilities by developing and piloting AI-enabled healthcare programs with the objective of converting clinical applications into scalable, revenue-generating services. At the same time, the Company’s accumulated healthcare data assets have created opportunities for higher-value applications in chronic disease management, pharmaceutical research, and other data-driven healthcare services.

By integrating AI technologies, wearable devices, and its existing digital healthcare infrastructure, Pomdoctor is developing a more integrated ecosystem designed to connect patient services, chronic disease management, healthcare institutions, pharmaceutical companies, and data-driven applications. The Company believes this integrated approach can progressively transform data assets from primarily operational resources into sources of incremental commercial value. The Company’s AI-enabled chronic disease subscriptions and pharmaceutical RWS/RWD services are at an early stage of commercialization.

Building a Four-Tier Revenue Structure

Pomdoctor’s current business model is structured around four interconnected revenue tiers:

B2C Basic Healthcare Services — providing an entry point for patients and users through core digital healthcare services;AI-Enabled Chronic Disease Membership Subscriptions — extending user relationships through personalized, technology-enabled chronic disease management and recurring subscription services;B2B Enterprise and Hospital Services — leveraging the Company’s healthcare capabilities and institutional relationships to provide digital solutions and services to enterprises and healthcare institutions; andPharmaceutical RWS/RWD Services — leveraging accumulated healthcare data, clinical experience, and AI capabilities to support pharmaceutical companies in real-world studies (“RWS”) and real-world data (“RWD”) applications.

Together, these four tiers are designed to create a progressive value chain rather than operate as independent revenue streams. B2C services provide the foundation for patient engagement and healthcare data accumulation; AI-enabled chronic disease subscriptions deepen patient relationships and enhance recurring revenue; B2B enterprise and hospital services broaden the Company’s institutional reach and commercial applications; and the resulting data and healthcare infrastructure create a foundation for higher-value pharmaceutical RWS/RWD services.

Pomdoctor believes this interconnected model is designed for longer-term growth opportunities, while creating a potential flywheel effect in which expanding users, healthcare services, institutional relationships, AI applications, and data assets reinforce one another and support the Company’s ongoing transition toward more value-based healthcare monetization.

Management Commentary

Mr. Zhenyang Shi, Chairman and Chief Executive Officer of Pomdoctor, commented: “Since our inception, we have continuously sought distinctive and sustainable ways to create value as the healthcare industry evolves through successive waves of business model and technological change. From our early focus on digital healthcare services, to the development of subscription-based offerings and B2B healthcare services, and now to AI-enabled chronic disease management and data-driven pharmaceutical services, we have consistently endeavored to invest ahead of emerging industry trends while building upon our existing capabilities.

“Today, Pomdoctor is focused on further strengthening our four-tier revenue structure and integrating these businesses into a more comprehensive healthcare ecosystem. We believe the combination of healthcare services, AI, institutional capabilities, and data assets provides a scalable foundation for our next stage of growth. With our experience and capabilities in China, we are also exploring opportunities to replicate and adapt this model in key international markets. We remain committed to continuously improving our business model, expanding our ecosystem, and translating our operational capabilities and innovation into sustainable long-term value for our shareholders.”

About POMDOCTOR LIMITED

POMDOCTOR LIMITED (NASDAQ: POM) is a digital healthcare company focused on advancing AI-enabled healthcare solutions and expanding predictive healthcare capabilities. The Company leverages physician resources, wearable technologies, artificial intelligence, healthcare payment networks and real-world healthcare data to support more personalized, continuous and data-driven healthcare services. Building upon its established healthcare platform and physician network, POM is pursuing the development of a predictive healthcare data and services infrastructure designed to improve healthcare outcomes and create long-term value for patients, healthcare providers and other ecosystem participants. For more information, please visit the Company’s website: http://ir.7shiliu.com.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These statements are made under the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding: the Company’s strategic evolution from a traffic monetization model toward value-based healthcare payment and monetization; the Company’s plans to further strengthen its four-tier revenue structure spanning B2C basic healthcare services, AI-enabled chronic disease membership subscriptions, B2B enterprise and hospital services, and pharmaceutical RWS/RWD services, and to integrate these businesses into a more comprehensive healthcare ecosystem; the Company’s development and piloting of AI-enabled healthcare programs and its ability to convert clinical applications into scalable, revenue-generating services; the Company’s plans to integrate AI technologies, wearable devices and its existing digital healthcare infrastructure, and its belief that such integration can progressively transform data assets into sources of incremental commercial value; the Company’s expectations regarding growth in recurring subscription revenue, the expansion of its institutional reach and relationships with healthcare institutions, including public hospitals, and pharmaceutical companies, and the development of higher-value pharmaceutical RWS/RWD services; the Company’s belief that its interconnected business model is designed to balance near-term revenue generation and cash flow with longer-term growth opportunities and to create a potential flywheel effect; the Company’s exploration of opportunities to replicate and adapt its business model in key international markets; and the anticipated benefits of the Company’s strategy for patients, healthcare providers, pharmaceutical companies, shareholders and other ecosystem participants, including sustainable long-term value creation. Investors can identify many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “aims,” “estimates,” “projects,” “intends,” “plans,” “pursues,” “positions,” “will,” “would,” “should,” “could,” “may” or other similar expressions. These forward-looking statements are based on the Company’s current expectations, assumptions and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs, and involve known and unknown risks and uncertainties, many of which are beyond the Company’s control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and investors are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements speak only as of the date of this announcement, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, except as may be required by law.

Actual results may differ materially from those expressed or implied in these forward-looking statements due to a number of factors and uncertainties. Investors are urged to review the section entitled “Item 3. Key Information—D. Risk Factors” in the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2025 filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 14, 2026, and the Company’s other filings with the SEC, which are available on the SEC’s website at www.sec.gov.

For more information, please contact:

POMDOCTOR LIMITED
Investor Relations Department
Email: ir@7lk.com

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com

View original content:https://www.prnewswire.com/news-releases/pomdoctor-limited-advances-strategic-evolution-from-traffic-monetization-to-value-based-healthcare-payment-302927633.html

SOURCE POMDOCTOR LIMITED

Related Topics:
Continue Reading

Technology

Ashling’s Morgan Conque Named SMB Leader of the Year Finalist at the 2026 U.S. Forces in Business Awards

Published

56 minutes ago

on

November 6, 2026

By

The world’s largest celebration of veteran talent lands in Dallas, Texas, on December 10 to spotlight outstanding former service members driving American business forward.

CHICAGO, Nov. 6, 2026 /PRNewswire/ — Morgan Conque, Vice President of Go-to-Market at Ashling, a leading global provider of AI and Automation consulting and development services, has been named a finalist for SMB Leader of the Year at the 2026 U.S. Forces in Business Awards. Now in its ninth year, the program is the world’s largest celebration of military veterans in the civilian workforce, with this year’s shortlist selected from hundreds of nominations.

A U.S. Army officer commissioned through ROTC, Morgan served with NATO forces in Germany, ran personnel operations in South Korea, and advised an Afghan army hospital, where she helped cut the medical evacuation cycle from 17 hours to 3. She concluded her service as the Medical Operations and Logistics Officer for the First Cavalry Division, supporting more than 18,000 soldiers.

Morgan’s military experience translated into business leadership from the start. Following her service, she led branch operations for a large specialty infusion pharmacy team, then moved into intelligent automation and rapidly expanded her scope from bid manager to leading sales platforms, enablement, content, and strategy. Her education supports that trajectory, including a Bachelor of Science in Biology from Seattle University, a Master of Science in Biosecurity and Disaster Preparedness from Saint Louis University, and an Executive MBA from Baylor University’s Hankamer School of Business.

Today, Morgan leads go-to-market strategy at Ashling, aligning sales, marketing, and partnership teams to drive the fast-paced growth and navigate the ever evolving market landscape. “I look back on my transition into AI and automation as serendipitous,” Conque said. “The discipline I built in the Army, leading teams, making decisions with incomplete information, and staying accountable to the mission, carried directly into this field and suited me well. I remain fascinated by the conversations I’m part of and excited about where the industry is headed.”

More than 200,000 service members leave active duty in the United States each year, yet research by ZipRecruiter and the Call of Duty Endowment found that almost one-third of veterans are underemployed, a rate 15.6% higher than among their non-veteran peers. Morgan’s career is a testament to what that talent can achieve. Established in 2018, the Forces in Business Awards celebrate veteran role models like her, reflecting the breadth of industries and professional disciplines where former service members are making their mark.

Rear Admiral (Ret.) Milton “Jamie” Sands III, President and CEO of Special Operations Warrior Foundation, official charity partner of the U.S. Forces in Business Awards, said: “Congratulations to this year’s finalists, whose achievements demonstrate the value military experience brings to business. Service develops leaders who take responsibility, build strong teams, and deliver under pressure. These finalists are putting those qualities to work in new ways, strengthening their organizations and communities while helping others see what is possible after military service.”

Marshall Sied, Co-Founder and Co-CEO of Ashling, said: “Morgan’s experience as a military veteran has clearly laid a strong foundation for the evolution of her career.  At Ashling, she balances our fast-paced industry and constantly evolving capabilities with enthusiasm and clarity.  Morgan has the unique ability of being a creative thinker, inspiring team leader, and strong operational executor all at once. We are honored to have Morgan help lead the charge on many of our most mission-critical initiatives. She is a very deserving finalist.”

Winners will be announced on December 10, 2026, at a black-tie gala in the Lincoln Ballroom at the Hilton Dallas Lincoln Centre, hosted by longtime CBS News anchor and Gold Star son Doug Dunbar.

About Ashling

Ashling is a global AI and automation consulting and development firm specializing in digital process transformation. They align on what value means for enterprises, design, build and manage solutions that work from pilot to production, and architect an operating model designed for rapid deployment and compounding success.

Ashling’s delivery accelerators get clients to production 5x faster and prove ROI sooner, backed by a delivery team of forward-deployed AI pods and award-winning innovation. Ashling is the firm enterprise clients trust, with over 400 clients across industries, an 86 NPS, and an unwavering commitment to the business outcomes they deliver.

About the Forces in Business Awards

The Forces in Business Awards is the world’s largest business celebration of the military community. Taking place in the United States and United Kingdom, the Awards program is the leading platform for uncovering and showcasing the achievements and talents of veterans, presenting them as visible role models for transitioning service members and recognizing aspirational employers for current and former servicemen and women. The prestigious events promote the value that veterans add to the economy after service.

Media Contact

Madison Ramsay, Senior Marketing Manager, Ashling madison.ramsay@ashlingpartners.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ashlings-morgan-conque-named-smb-leader-of-the-year-finalist-at-the-2026-us-forces-in-business-awards-302932150.html

SOURCE Ashling Partners

Continue Reading

Technology

Diamond Foundry Announces First-Ever D200mm Single-Crystal Diamond

Published

56 minutes ago

on

November 6, 2026

By

Breakthrough culminates 25 years of scientific pursuit and establishes a new scale for single-crystal diamond

SAN FRANCISCO, Nov. 6, 2026 /PRNewswire/ — Diamond Foundry Inc. today announced a major milestone in the history of materials technology: the creation of the first-ever D200mm single-crystal diamond, measuring 200 millimeters in diameter.

Diamond Foundry creates the world’s first 200mm single-crystal diamond, bringing diamond to semiconductor wafer scale.

The achievement marks a fundamental step forward in humanity’s ability to manufacture diamond as a technology material at semiconductor-relevant scale.

The announcement accompanies a keynote by Diamond Foundry CEO Martin Roscheisen, delivered by video at CarbonSemi 2026 in Ningbo, China. Watch the keynote: https://youtu.be/ae0XQBDlLMQ.

Diamond has long been recognized as an extraordinary material for technology. It combines the highest thermal conductivity with exceptional mechanical strength, electrical insulation, optical properties, and the potential for extreme electronic performance. Yet its use in advanced technology has been constrained by one basic limitation: size.

Diamond Foundry’s D200mm breakthrough changes that.

Producing single-crystal diamond at D200mm scale required overcoming fundamental challenges in crystal growth, plasma physics, reactor engineering, materials science, process control, and manufacturing. The result is not an assembly of individual diamond pieces and not a polycrystalline diamond wafer. It is a single-crystal diamond at D200mm scale.

“This is one of those milestones that once seemed almost impossible,” said Martin Roscheisen, CEO of Diamond Foundry Inc. “Hundreds of DF engineers, scientists, and technicians contributed to us getting here. It is the accumulated result of countless experiments, failures, inventions, rebuilt machines, and insights over more than a decade.”

Roscheisen particularly recognized Stefan Gsell and Martin Fischer, whose work on scaling single-crystal diamond began 25 years ago.

“Stefan and Martin pursued this goal for 25 years,” Roscheisen said. “There are very few examples in technology of someone sticking to a really hard scientific challenge with that level of perseverance. They kept going when the prevailing view was that single-crystal diamond simply could not be made at this scale. Today, the perseverance shows as the first-ever D200mm single-crystal diamond. And best of all, it makes D300mm predictable as well.”

From Gemstone Dimensions to Semiconductor Dimensions

The semiconductor industry is built around the ability to manufacture extraordinary materials at wafer scale. Silicon’s progression toward larger wafers transformed electronics by allowing increasingly sophisticated devices to be manufactured economically and repeatably.

Diamond has never had an equivalent scaling path.

Natural diamond is constrained by geology. Conventional lab-grown diamond has historically been constrained to relatively small crystal dimensions. Even as the extraordinary properties of diamond became increasingly relevant to high-power electronics, AI computing, optics, quantum systems, and other advanced technologies, crystal size remained a fundamental bottleneck.

The D200mm single-crystal diamond milestone demonstrates a path beyond that limitation.

For Diamond Foundry, the achievement is part of a broader effort to turn single-crystal diamond from a scarce material measured in gemstones into a tech-industrial semiconductor substrate manufactured at scale.

The implications are particularly significant as computing systems encounter increasingly severe thermal constraints. Modern AI processors concentrate enormous amounts of power into microscopic regions of silicon. Diamond’s exceptional thermal conductivity can spread that heat at the material level, creating new possibilities for chip architectures, power densities, reliability, and cooling.

Twenty-Five Years of Perseverance

The D200mm achievement has roots extending well beyond Diamond Foundry itself.

For 25 years, Gsell and Fischer pursued the underlying scientific and engineering challenge of growing high-quality single-crystal diamond of scalable size. Their work ultimately became part of a much larger effort involving hundreds of people across Diamond Foundry.

The milestone reflects advances spanning plasma generation, growth chemistry, reactor architecture, crystal engineering, thermal management, metrology, automation, and manufacturing.

“Technology history is often written around the moment something finally works,” Roscheisen said. “But that moment rests on the people who were willing to spend years — sometimes decades — making it work. This diamond exists because hundreds of people contributed, and because a few people refused to give up on the idea for 25 years.”

A New Scale for Diamond

Diamond Foundry views D200mm not as an endpoint, but as the beginning of a new manufacturing era for diamond.

The company is developing single-crystal diamond for semiconductor and advanced-technology applications where diamond’s combination of thermal, mechanical, electrical, and optical properties can enable performance beyond the limits of conventional materials.

The first D200mm crystal is shown as grown and unpolished — directly from the growth process.

For a material that nature forms only under extraordinary conditions deep inside the Earth, the significance is simple:

Single-crystal diamond has entered the wafer-scale era.

About Diamond Foundry Inc.

Diamond Foundry is the #1 producer of single-crystal diamond in the world. Founded in San Francisco, the company created the world’s first diamond wafer and is scaling volume production of chip substrates with a $2.77B EU Chips Act project in Spain.

Media contact: Jeff Yurek, j@df.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/diamond-foundry-announces-first-ever-d200mm-single-crystal-diamond-302931849.html

SOURCE Diamond Foundry

Continue Reading

Technology

Qued Ranks No. 5 on FreightWaves’ 2027 FreightTech 25, Its Third Straight Year on the List

Published

56 minutes ago

on

November 6, 2026

By

An independent panel ranked the AI appointment scheduling platform No. 5 of 25 companies selected from the 2027 FreightTech 100. FreightWaves announced the rankings Oct. 26 at the inaugural F3 Awards Dinner in Chattanooga.

BROADLANDS, Va., Nov. 6, 2026 /PRNewswire-PRWeb/ — Qued, a leader in developing sophisticated, automated appointment scheduling solutions for supply chain and logistics companies, today announced that it ranked No. 5 on the 2027 FreightTech 25, the FreightWaves list of 25 companies recognized for innovation across freight technology and transportation. FreightWaves revealed the list on Oct. 26 at the inaugural F3 Awards Dinner in Chattanooga, Tennessee.

Our customers earned this ranking. They book their appointments through Qued from inside the systems they already run, and we will keep building for the people who move freight every day.

This is the third year in a row Qued has made the FreightTech 25. Qued debuted at No. 6 in 2025 and ranked No. 3 in 2026.

The FreightTech 25 is selected from the FreightTech 100, a broader list of 100 companies FreightWaves recognizes for innovation in freight and supply chain technology. An independent panel ranks those 100 companies to set the top 25, and the accounting firm Henderson, Hutcherson & McCullough oversees the voting. FreightWaves recognized all 100 companies at the F3 Awards Dinner, where Sope Creek presented the 2027 FreightTech Awards.

“Appointment scheduling rarely makes headlines, so a third straight year on the FreightTech 25 means a lot to our team,” said Prasad Gollapalli, CEO and founder of Qued. “Our customers earned this ranking. They book their appointments through Qued from inside the systems they already run, and we will keep building for the people who move freight every day.”

Qued’s platform uses machine learning to find the best appointment slots in real time, weighing ETAs, facility capacity, historical performance, and the specific requirements of each location. Qued connects directly to the transportation management system a broker, 3PL, or carrier already runs, and it books through facility portals, email, and AI voice calls to facilities that only book by phone.

The full 2027 FreightTech 25 is published on FreightWaves.com.

About Qued

Qued is a cloud-based, AI-powered smart workflow automation platform transforming load appointment scheduling for brokers, 3PLs, and carriers. By automating the scheduling process, Qued eliminates manual work, simplifies multi-stop load appointments, and ensures seamless coordination across the supply chain, improving both operational efficiency and customer satisfaction. For more information, visit www.qued.com or contact us at contact.us@qued.com.

Media Contact

Adam Robinson, Qued, 1 2148720780, adam@the-robinson-agency.com, https://www.qued.com/

View original content:https://www.prweb.com/releases/qued-ranks-no-5-on-freightwaves-2027-freighttech-25-its-third-straight-year-on-the-list-302931740.html

SOURCE Qued

Continue Reading

Trending